BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Reports Preliminary $1.7B Pipeline Valuation From Joint Venture Partner 

Oncotelic Therapeutics (OTCQB: OTLC) today announced that joint venture partner GMP Bio has received an independent Frost & Sullivan (Hong Kong) valuation estimating the potential value of its therapeutic pipeline at approximately $1.7 billion, implying about $765 million for Oncotelic’s 45% stake. The non-binding, forward-looking analysis does not represent fair value under U.S. GAAP, and Oncotelic has initiated a separate ASC-compliant valuation that will support future financial reporting. Depending on the results, the Company may record a higher carrying value for its minority interest in upcoming periods, consistent with applicable fair-value measurement standards. CEO Dr. Vuong Trieu said the valuation affirms progress across the OT-101 program and the Deciparticle(TM) platform, with the JV advancing OT-101 into Phase 3 PDAC and Phase 2 combination trials, expanding its nanomedicine pipeline, and operating a GMP-licensed facility in San Diego. The JV is preparing for a potential Hong Kong IPO in late 2026, subject to market and regulatory conditions.

To view the full press release, visit https://ibn.fm/Vtkd1

About Oncotelic Therapeutics Inc.

Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on the development of oncology and immunotherapy products. The company’s mission is to address high-unmet-need cancers and rare pediatric indications with innovative, late-stage therapeutic candidates. In addition to its directly owned and developed drug pipeline, Oncotelic benefits from the robust portfolio of inventions created by its CEO, Dr. Vuong Trieu, who has filed more than 150 patent applications and holds 39 issued U.S. patents. Beyond its internal programs, the company also licenses and codevelops select drug candidates through joint ventures. Currently, Oncotelic owns 45% of GMP Bio, a joint venture under Trieu’s leadership and guidance, which is advancing its own pipeline of drug candidates that further complement and strengthen Oncotelic’s strategic position in oncology and rare disease therapeutics.

NOTE TO INVESTORS: The latest news and updates relating to OTLC are available in the company’s newsroom at https://ibn.fm/OTLC

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN